BIOSIM
Accelerating the commercialisation of a disruptive analytical technology which enables the biopharmaceutical industry to manufacture drugs faster, cheaper and with greater regulatory confidence
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0BIOSIM project word cloud
Explore the words cloud of the BIOSIM project. It provides you a very rough idea of what is the project "BIOSIM" about.
Project "BIOSIM" data sheet
The following table provides information about the project.
| Coordinator |
VALITACELL LTD
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Project website | http://www.valitacell.com |
| Total cost | 2˙029˙325 € |
| EC max contribution | 2˙029˙325 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2016-2017 |
| Funding Scheme | SME-2 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-10-01 to 2019-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | VALITACELL LTD | IE (DUBLIN 2) | coordinator | 2˙029˙325.00 |
Map
Project objective
The global Biologic drug [including Vaccines] market exceeds €500 bn with an annual growth of 8%. Biopharmaceutical companies need to be able to produce these new biologic drugs faster and cheaper to meet the needs of patients, regulators and the governments and insurance companies who are paying for these high cost therapies. Valitacell is an Irish SME which currently supplies this market and is a validated supplier to a growing number of market leaders including GE Healthcare & MedImmune.
BIOSIM will accelerate the commercialisation of our ChemStress technology platform for this industry. Scientifically these tests measure a cell’s performance when exposed to small molecule chemicals which simulate the stresses that the cell will experience in the scaled-up manufacturing process. When applied together they can reduce the average Cell Line Development stage of drug manufacture from 16 to 6 months and reduce the average cost from €2.3million to €1.1 million.
BIOSIM will support: the demonstration of ChemStress at 4 leading biopharmaceutical manufacturing sites resulting in the generation of a customer endorsed value proposition; productise the ChemStress platform for the Biopharmmaceutical industry; refinement, scale-up and validation of the product manufacture; priming the sales & marketing for product launch. . ChemStress will realise €40m of end-user product sales and support 50 jobs in the 5 years following the project. ChemStress will provide EU Biomanufacturers with the opportunity to maintain their leadership position by implementing this disruptive innovation and realizing cost reductions. ChemStress will reduce the cost of biological drugs through lower manufacturing costs so enabling EU governments to provide these drugs to EU citizens at a lower cost.
Deliverables
| CE marked product | Demonstrators, pilots, prototypes | 2020-02-11 12:50:34 |
| Peer reviewed publication submitted | Demonstrators, pilots, prototypes | 2020-02-11 12:50:34 |
| Results exchanged | Demonstrators, pilots, prototypes | 2020-02-11 12:50:34 |
Take a look to the deliverables list in detail: detailed list of BIOSIM deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOSIM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BIOSIM" are provided by the European Opendata Portal: CORDIS opendata.